Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Osteoarthritis Pipeline Review, H2 2017 - Therapeutics Analysis of 59 Companies & Drug Profiles - Research and Markets

Research and Markets
Posted on: 28 Aug 17

The "Osteoarthritis - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Osteoarthritis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 8, 16, 9, 44 and 11 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 5 molecules, respectively.

Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Osteoarthritis - Overview
  3. Osteoarthritis - Therapeutics Development
  4. Osteoarthritis - Therapeutics Assessment
  5. Osteoarthritis - Companies Involved in Therapeutics Development
  6. Osteoarthritis - Drug Profiles
  7. Osteoarthritis - Dormant Projects
  8. Osteoarthritis - Discontinued Products
  9. Osteoarthritis - Product Development Milestones
  10. Appendix

Companies Mentioned

  • 4P-Pharma SAS
  • AbbVie Inc
  • Abiogen Pharma SpA
  • Amura Holdings Ltd
  • Anterogen Co Ltd
  • Asahi Kasei Pharma Corp
  • Axsome Therapeutics Inc
  • Biopharm GmbH
  • Dong-A Socio Holdings Co Ltd
  • Eli Lilly and Company
  • Evgen Pharma Plc
  • Galapagos NV
  • Gemphire Therapeutics Inc
  • Genequine Biotherapeutics GmbH
  • GlaxoSmithKline Plc
  • InKemia IUCT Group SA
  • International Stem Cell Corp
  • Jeil Pharmaceutical Co Ltd
  • K-Stemcell Co Ltd
  • Kang Stem Biotech Co Ltd
  • Lateral Pharma Pty Ltd
  • Levolta Pharmaceuticals Inc
  • LG Chem, Ltd.
  • Marina Biotech Inc
  • Medivir AB
  • Merck KGaA
  • Novartis AG
  • NovelMed Therapeutics Inc
  • Osteologix Holdings Plc
  • Pfizer Inc
  • Pharmalink AB
  • Takeda Pharmaceutical Company Ltd
  • TissueGene Inc
  • Traverse Biosciences Inc
  • Zimmer Biomet Holdings Inc

For more information about this report visit https://www.researchandmarkets.com/research/nxsnnj/osteoarthritis

View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005559/en/

Business Wire
www.businesswire.com

Last updated on: 28/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.